These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 6356316)

  • 21. Effects of a gastric partitioning operation for morbid obesity on the secretion of gastric inhibitory polypeptide and pancreatic polypeptide.
    Amland PF; Jorde R; Kildebo S; Burhol PG; Giercksky KE
    Scand J Gastroenterol; 1984 Sep; 19(6):857-61. PubMed ID: 6393318
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Endocrine pancreas in cystic fibrosis: an immunohistochemical study.
    Iannucci A; Mukai K; Johnson D; Burke B
    Hum Pathol; 1984 Mar; 15(3):278-84. PubMed ID: 6365738
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Initially more rapid small intestinal glucose delivery increases plasma insulin, GIP, and GLP-1 but does not improve overall glycemia in healthy subjects.
    Chaikomin R; Doran S; Jones KL; Feinle-Bisset C; O'Donovan D; Rayner CK; Horowitz M
    Am J Physiol Endocrinol Metab; 2005 Sep; 289(3):E504-7. PubMed ID: 15886226
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The insulinotropic effect of GIP is impaired in patients with chronic pancreatitis and secondary diabetes mellitus as compared to patients with chronic pancreatitis and normal glucose tolerance.
    Knop FK; Vilsbøll T; Højberg PV; Larsen S; Madsbad S; Holst JJ; Krarup T
    Regul Pept; 2007 Dec; 144(1-3):123-30. PubMed ID: 17692937
    [TBL] [Abstract][Full Text] [Related]  

  • 25. What do we know about the secretion and degradation of incretin hormones?
    Deacon CF
    Regul Pept; 2005 Jun; 128(2):117-24. PubMed ID: 15780431
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Consensus on the diagnosis and management of changes in carbohydrate metabolism in cystic fibrosis].
    Barrio Castellanos R ; Cos Blanco A ; García García E ; Gussinyé Cañadell M ; Merino Torres J ; Muñoz Calvo M
    An Esp Pediatr; 2000 Dec; 53(6):573-9. PubMed ID: 11148156
    [TBL] [Abstract][Full Text] [Related]  

  • 27. VIP reduction in the pancreas of F508del homozygous CF mice and early signs of Cystic Fibrosis Related Diabetes (CFRD).
    Semaniakou A; Chappe F; Anini Y; Chappe V
    J Cyst Fibros; 2021 Sep; 20(5):881-890. PubMed ID: 34034984
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Postprandial release of gastric inhibitory polypeptide (GIP) and pancreatic polypeptide in dogs with pancreatic acinar atrophy. Correction of blunted GIP response by addition of pancreatic enzymes to a meal.
    Rogers WA; O'Dorisio TM; Johnson SE; Cataland S; Stradley RP; Sherding RG
    Dig Dis Sci; 1983 Apr; 28(4):345-9. PubMed ID: 6831998
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pancreatic endocrine function in cystic fibrosis.
    Moran A; Diem P; Klein DJ; Levitt MD; Robertson RP
    J Pediatr; 1991 May; 118(5):715-23. PubMed ID: 2019925
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cystic fibrosis in adults: an autopsy study.
    Vawter GF; Shwachman H
    Pathol Annu; 1979; 14 Pt 2():357-82. PubMed ID: 547223
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Various factors related to carbohydrate metabolism. Gastro-entero-pancreatic hormones].
    Matsuda M; Kaneko T
    Nihon Rinsho; 1989 Nov; 47(11):2415-9. PubMed ID: 2574755
    [No Abstract]   [Full Text] [Related]  

  • 32. Pancreatic morphology and function in adult patients with cystic fibrosis.
    Van Haren EH; Hopman WP; Rosenbusch G; Jansen JB; Van Herwaarden CL
    Scand J Gastroenterol; 1992 Aug; 27(8):695-8. PubMed ID: 1439553
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cystic fibrosis associated islet changes may provide a basis for diabetes. An immunocytochemical and morphometrical study.
    Löhr M; Goertchen P; Nizze H; Gould NS; Gould VE; Oberholzer M; Heitz PU; Klöppel G
    Virchows Arch A Pathol Anat Histopathol; 1989; 414(2):179-85. PubMed ID: 2492695
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Endocrine disorders of the pancreas.
    Richardson GO
    Practitioner; 1968 Apr; 200(198):494-501. PubMed ID: 4298289
    [No Abstract]   [Full Text] [Related]  

  • 35. Insulin resistance in a young man with cystic fibrosis.
    Geffner ME; Lippe BM; Itami RM; Kaplan SA; Gillard BK; Levin SR; Taylor IL
    Am J Dis Child; 1984 Jul; 138(7):677-80. PubMed ID: 6375349
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cystic fibrosis and nesidioblastosis.
    Brown RE; Madge GE
    Arch Pathol; 1971 Jul; 92(1):53-7. PubMed ID: 4933308
    [No Abstract]   [Full Text] [Related]  

  • 37. Diabetes mellitus in cystic fibrosis: a review.
    Dodge JA; Morrison G
    J R Soc Med; 1992; 85 Suppl 19(Suppl 19):25-8. PubMed ID: 1597837
    [No Abstract]   [Full Text] [Related]  

  • 38. Vasoactive intestinal peptide as a regulator of exocrine function and as a possible factor in cystic fibrosis.
    Heinz-Erian P; Said SI
    Ann N Y Acad Sci; 1988; 527():568-73. PubMed ID: 3291701
    [No Abstract]   [Full Text] [Related]  

  • 39. Ganglioneuromatosis involving the small intestine and pancreas of a child and causing hypersecretion of vasoactive intestinal polypeptide.
    Shulman DI; McClenathan DT; Harmel RP; Qualman SJ; O'Dorisio TM
    J Pediatr Gastroenterol Nutr; 1996 Feb; 22(2):212-8. PubMed ID: 8642497
    [No Abstract]   [Full Text] [Related]  

  • 40. Involvement of the small intestine in cystic fibrosis.
    Jodl J; Lojda Z; Simankova N; Fric P
    Acta Paediatr Scand; 1971 May; 60(3):367. PubMed ID: 5579872
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.